Hanmi Pharmaceutical expects U.S. FDA approval for 2 new drugs
The Pharma Data
JANUARY 17, 2021
plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields. are expected to be approved by the U.S. .
Let's personalize your content